You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Boehringer Ingelheim
Dow
Harvard Business School
Baxter

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROSPIUM CHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Trospium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00465959 Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Alkermes, Inc. Phase 1/Phase 2 2007-04-01 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00465959 Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Endo Pharmaceuticals Phase 1/Phase 2 2007-04-01 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00800462 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Ontario Neurotrauma Foundation Phase 4 2008-03-01 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00800462 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Toronto Rehabilitation Institute Phase 4 2008-03-01 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Completed Allergan Phase 4 2009-04-01 This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
NCT00932022 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Completed Allergan Phase 4 2009-07-01 This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects Completed Allergan Phase 1 2009-10-01 The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trospium Chloride

Condition Name

Condition Name for Trospium Chloride
Intervention Trials
Schizophrenia 6
Overactive Bladder 4
Schizophrenia; Psychosis 2
Intestinal Obstruction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trospium Chloride
Intervention Trials
Schizophrenia 6
Urinary Bladder, Overactive 5
Intestinal Obstruction 2
Spinal Cord Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trospium Chloride

Trials by Country

Trials by Country for Trospium Chloride
Location Trials
United States 22
Canada 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trospium Chloride
Location Trials
California 5
Georgia 2
Ohio 2
Texas 2
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trospium Chloride

Clinical Trial Phase

Clinical Trial Phase for Trospium Chloride
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trospium Chloride
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 5
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trospium Chloride

Sponsor Name

Sponsor Name for Trospium Chloride
Sponsor Trials
Allergan 5
Karuna Pharmaceuticals 4
University Medicine Greifswald 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trospium Chloride
Sponsor Trials
Industry 13
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Boehringer Ingelheim
Medtronic
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.